Cargando…

Patients'perspectives and motivators to participate in clinical trials with novel therapies for rheumatoid arthritis

Background and Purposes–Successful advances in the treatment of rheumatoid arthritis rely on enrolment of patients into clinical trials with novel agents. The aim of this study was to assess the patients' perspectives and motivators to participate in clinical trials. Methods–Consecutive patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Udrea, G, Dumitrescu, B, Purcarea, M, Balan, I, Rezus, E, Deculescu, D
Formato: Texto
Lenguaje:English
Publicado: Carol Davila University Press 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018984/
https://www.ncbi.nlm.nih.gov/pubmed/20108545
_version_ 1782196136281374720
author Udrea, G
Dumitrescu, B
Purcarea, M
Balan, I
Rezus, E
Deculescu, D
author_facet Udrea, G
Dumitrescu, B
Purcarea, M
Balan, I
Rezus, E
Deculescu, D
author_sort Udrea, G
collection PubMed
description Background and Purposes–Successful advances in the treatment of rheumatoid arthritis rely on enrolment of patients into clinical trials with novel agents. The aim of this study was to assess the patients' perspectives and motivators to participate in clinical trials. Methods–Consecutive patients with rheumatoid arthritis attending three rheumatology departments in Romania underwent structured questionnaire interview regarding the motivation/possible causes of acceptance or drawbacks to participate in a clinical trial. Results–A total of 96 patients, mean age 48, 30% men 70% women answered. Response rate was 95%. Previous participation in other clinical trials was 23%. Patients were highly motivated to participate in order to help themselves or other patients and to enhance the knowledge about the disease. Patients were prone to ask for advice about their enrolment in the study from the family and their current physicians, including the general practitioner. The need for supplementary information about the study was felt because they had not dared to ask for the information, although they trusted their current doctor. A high percentage considered payment and free complete blood tests as a stimulus, especially among patients with lower levels of education (p=0.03, Fisher's ANOVA). Advertising for investigational medical product for purposes of patient recruitment was important for 57%, not only for safety or trust, but also for transparency and as a tool to get information. 73% of the persons agreed to the usefulness of patients association. 26% of them were willing to be actively involved, especially to report and include adverse events in the study settings. 58% were motivated if they knew other patients were consulted. Patients were not motivated because of the adverse events, placebo effect, treatment discontinuation, limited previous experience, availability of alternative therapies and doctor reimbursement for the study. Conclusions–The current study suggests that awareness of factors (positive and negative) which influence motivation to participate in a clinical trial may help to refine patient's education and to consider new strategies for future trials.
format Text
id pubmed-3018984
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Carol Davila University Press
record_format MEDLINE/PubMed
spelling pubmed-30189842011-03-03 Patients'perspectives and motivators to participate in clinical trials with novel therapies for rheumatoid arthritis Udrea, G Dumitrescu, B Purcarea, M Balan, I Rezus, E Deculescu, D J Med Life Case Presentation Background and Purposes–Successful advances in the treatment of rheumatoid arthritis rely on enrolment of patients into clinical trials with novel agents. The aim of this study was to assess the patients' perspectives and motivators to participate in clinical trials. Methods–Consecutive patients with rheumatoid arthritis attending three rheumatology departments in Romania underwent structured questionnaire interview regarding the motivation/possible causes of acceptance or drawbacks to participate in a clinical trial. Results–A total of 96 patients, mean age 48, 30% men 70% women answered. Response rate was 95%. Previous participation in other clinical trials was 23%. Patients were highly motivated to participate in order to help themselves or other patients and to enhance the knowledge about the disease. Patients were prone to ask for advice about their enrolment in the study from the family and their current physicians, including the general practitioner. The need for supplementary information about the study was felt because they had not dared to ask for the information, although they trusted their current doctor. A high percentage considered payment and free complete blood tests as a stimulus, especially among patients with lower levels of education (p=0.03, Fisher's ANOVA). Advertising for investigational medical product for purposes of patient recruitment was important for 57%, not only for safety or trust, but also for transparency and as a tool to get information. 73% of the persons agreed to the usefulness of patients association. 26% of them were willing to be actively involved, especially to report and include adverse events in the study settings. 58% were motivated if they knew other patients were consulted. Patients were not motivated because of the adverse events, placebo effect, treatment discontinuation, limited previous experience, availability of alternative therapies and doctor reimbursement for the study. Conclusions–The current study suggests that awareness of factors (positive and negative) which influence motivation to participate in a clinical trial may help to refine patient's education and to consider new strategies for future trials. Carol Davila University Press 2009-04-15 2009-04-25 /pmc/articles/PMC3018984/ /pubmed/20108545 Text en ©Carol Davila University Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Presentation
Udrea, G
Dumitrescu, B
Purcarea, M
Balan, I
Rezus, E
Deculescu, D
Patients'perspectives and motivators to participate in clinical trials with novel therapies for rheumatoid arthritis
title Patients'perspectives and motivators to participate in clinical trials with novel therapies for rheumatoid arthritis
title_full Patients'perspectives and motivators to participate in clinical trials with novel therapies for rheumatoid arthritis
title_fullStr Patients'perspectives and motivators to participate in clinical trials with novel therapies for rheumatoid arthritis
title_full_unstemmed Patients'perspectives and motivators to participate in clinical trials with novel therapies for rheumatoid arthritis
title_short Patients'perspectives and motivators to participate in clinical trials with novel therapies for rheumatoid arthritis
title_sort patients'perspectives and motivators to participate in clinical trials with novel therapies for rheumatoid arthritis
topic Case Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018984/
https://www.ncbi.nlm.nih.gov/pubmed/20108545
work_keys_str_mv AT udreag patientsperspectivesandmotivatorstoparticipateinclinicaltrialswithnoveltherapiesforrheumatoidarthritis
AT dumitrescub patientsperspectivesandmotivatorstoparticipateinclinicaltrialswithnoveltherapiesforrheumatoidarthritis
AT purcaream patientsperspectivesandmotivatorstoparticipateinclinicaltrialswithnoveltherapiesforrheumatoidarthritis
AT balani patientsperspectivesandmotivatorstoparticipateinclinicaltrialswithnoveltherapiesforrheumatoidarthritis
AT rezuse patientsperspectivesandmotivatorstoparticipateinclinicaltrialswithnoveltherapiesforrheumatoidarthritis
AT deculescud patientsperspectivesandmotivatorstoparticipateinclinicaltrialswithnoveltherapiesforrheumatoidarthritis